Background Three‐weekly high‐dose cisplatin (100 mg/m2) is considered the standard
systemic regimen given concurrently with postoperative or definitive radiotherapy in locally …

Background The optimal cumulative dose and timing of cisplatin administration in various
concurrent chemoradiotherapy protocols for nonmetastatic head and neck squamous cell …

Purpose Chemoradiation with cisplatin 100 mg/m2 given once every 3 weeks is the
standard of care in locally advanced head and neck squamous cell cancer (LAHNSCC) …

The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Head and Neck
Cancers provide treatment recommendations for cancers of the lip, oral cavity, pharynx …

Objective Human papillomavirus-positive (HPV+) head and neck squamous cell carcinoma
is increasing in incidence and appears to exhibit improved response to treatment and better …

Background This study presents oncologic outcomes after transoral robotic surgery
(TORS)±adjuvant therapy for oropharyngeal squamous cell carcinoma (SCC). Methods …

Background Due to unique biology and prognosis, precise identification of predictive
parameters is critical for p16+ oropharyngeal squamous cell carcinoma (OPSCC). Prior …

Human Papillomavirus (HPV) related oropharyngeal carcinoma (OPC) carries a better
prognosis compared with HPV‐counterparts, thereby pushing the adoption of de …

PURPOSE An ASCO provisional clinical opinion offers timely clinical direction to ASCO's
membership after publication or presentation of potentially practice-changing data from …

Simple Summary Head and neck squamous cell carcinoma (HNSCC) incidence has been
escalating in the last two decades, particularly in Western Europe and North America …